Jacob Galson, PhD, is the Vice President of Technology at Alchemab Therapeutics, where he spearheads the development and application of innovative technologies. Formerly the Bioinformatics lead at Kymab Ltd, Jake's team created the IntelliSelect® antibody discovery platform. A pioneer in immune receptor repertoire sequencing, he is a member of the AIRR community and has authored significant publications in the field. His work spans roles at The Oxford Vaccine Group, GSK Vaccines, and the University of Zürich, contributing to immunology, vaccine development, diagnostics, and antibody drug discovery. Jake holds a PhD in Medical Sciences and a First-Class BA in Biological Sciences from the University of Oxford.